Distribution of the Prevalence of Human Leukocyte Antigen (HLA)-B*57:01 Positivity in HIV-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Group

Basit Öğe Kaydı
dc.authoridSarıkaya, Burak/0000-0002-0026-1927
dc.authoridÇelik Ekinci, Semiha/0000-0002-6264-1685
dc.authoridtahmaz, alper/0000-0001-8674-2141
dc.authoridKose, Adem/0000-0002-1853-1243;
dc.authorwosidSarıkaya, Burak/KFC-0092-2024
dc.authorwosidÇelik Ekinci, Semiha/HPH-6509-2023
dc.authorwosidtahmaz, alper/JBI-6530-2023
dc.authorwosidKose, Adem/AAD-1226-2020
dc.authorwosidGunal, Ozgur/I-7882-2014
dc.contributor.authorBuyuktuna, Seyit Ali
dc.contributor.authorOksuz, Caner
dc.contributor.authorTahmaz, Alper
dc.contributor.authorSarigul Yildirim, Figen
dc.contributor.authorTurken, Melda
dc.contributor.authorGunal, Ozgur
dc.contributor.authorTopal, Seyma
dc.date.accessioned2024-08-04T20:10:24Z
dc.date.available2024-08-04T20:10:24Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHuman immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of in dividuals in all age groups. The landscape of HIV infection has changed significantly in recent years due to the introduction of effective combination antiretroviral therapies (ART). A key component of first -line ART regimens for HIV treatment is abacavir, a nucleoside HIV reverse transcriptase inhibitor. Although ab acavir is effective in suppressing viral replication and managing disease, its clinical utility is overshadowed by the potential for life -threatening hypersensitivity reactions in HLA-B*57:01-positive patients. In our country, local data obtained from various centers regarding the prevalence of HLA-B*57:01 in HIV -1 -infected patients are available. In this study, it was aimed to determine the prevalence of the HLA-B*57:01 genotype in HIV -infected patients who were followed up and treated in many regions of our country. This retrospective study consists of the data of the patients aged 18 years and over diagnosed with HIV -1 infection between 01.01.2019 and 31.07.2022. Age, gender, place of birth, mode of transmission of the disease, death status, CD4+ T cell count and HIV RNA levels at the first clinical presentation, HLA-B*57:01 positivity, and the method used, clinical stage of the disease, virological response time with the treatment they received were recorded from the patient files. Data were collected from 16 centers and each center used different methods to detect HLA-B*57:01. These methods were sequence -specific oligonucleotide probe hybridization (SSOP), DNA sequence -based typing (SBT), single -specific primer-polymerase chain reaction (SSP-PCR), allele -specific PCR (AS-PCR) and quantitative PCR (Q-PCR). A total of 608 HIV -infected individuals, 523 males (86%) and 85 females (14%), were included in the study. The mean age of the patients was 36.9 +/- 11.9 (18-73) years. The prevalence of HLA-B*57:01 allele was found to be 3.6% (22 patients). The number of CD4+ T lymphocytes in HLA-B*57:01 allele -positive patients was > 500/ mm(3) in 10 patients (45.5%), while the number of CD4+ T lymphocytes in HLA-B*57:01 negative pa- tients was > 500/mm(3) in 216 patients (36.9%) (p> 0.05). Viral load at the time of diagnosis was found to be lower in patients with positive HLA-B*57:01 allele but it was not statistically significant (p> 0.05). Although different treatment algorithms were used in the centers following the patients, it was observed that the duration of virological response was shorter in HLA-B*57:01 positive patients (p= 0.006). Although the presence of the HLA-B*57:01 allele has a negative impact due to its association with hypersensitivity, it is likely to continue to attract interest due to its association with slower progression of HIV infection and reduced risk of developing AIDS. In addition, although the answer to the question of whether it is cost-effective to screen patients for HLA-B*57:01 before starting an abacavir-containing ART regimen for the treatment of HIV infection is being sought, it seems that HIV treatment guidelines will continue to recommend screening to identify patients at risk in this regard.en_US
dc.identifier.doi10.5578/mb.20249903
dc.identifier.endpage38en_US
dc.identifier.issn0374-9096
dc.identifier.issue1en_US
dc.identifier.pmid38263938en_US
dc.identifier.scopus2-s2.0-85183460247en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage29en_US
dc.identifier.trdizinid1221997en_US
dc.identifier.urihttps://doi.org/10.5578/mb.20249903
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1221997
dc.identifier.urihttps://hdl.handle.net/11616/92762
dc.identifier.volume58en_US
dc.identifier.wosWOS:001201247600006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAnkara Microbiology Socen_US
dc.relation.ispartofMikrobiyoloji Bultenien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHLA-B*57 01en_US
dc.subjectHIVen_US
dc.subjectabacaviren_US
dc.subjectprevalenceen_US
dc.titleDistribution of the Prevalence of Human Leukocyte Antigen (HLA)-B*57:01 Positivity in HIV-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu